Zoetis Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/23/2026)
| Balance Sheet | Total Assets | 15,467,000,000.00 | ROE | 21.54 % |
| Balance Sheet | Total Equity | 3,415,000,000.00 | ROA | 17.28 % |
| Cashflow | Capital Expenditures | -621,000,000.00 | P/FCF | 14.64 |
| Cashflow | Free Cash Flow | 2,283,000,064.00 | – | – |
| Cashflow | Operating Cash Flow | 2,904,000,000.00 | P/CF | 11.51 |
| Income | Earnings per Share (diluted) | 6.02 | Div. Yield | 2.66 % |
| Income | Net Income | 2,673,000,000.00 | P/E | 12.51 |
| Income | Shares Outstanding | 417,700,000.00 | P/B | 10.03 |
| Income | Total Revenue | 9,467,000,000.00 | P/S | 3.53 |
Ratios calculated on: 10/14/2026
Company Description
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties. It also offers other product categories, such as nutritionals and agribusiness.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.zoetis.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more